X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dolutegravir (520) 520
index medicus (427) 427
humans (332) 332
infectious diseases (315) 315
raltegravir (259) 259
hiv (258) 258
hiv infections - drug therapy (238) 238
double-blind (227) 227
once-daily dolutegravir (217) 217
pharmacology & pharmacy (190) 190
immunology (188) 188
antiretroviral therapy (154) 154
antiretroviral-naive adults (132) 132
male (130) 130
microbiology (128) 128
human immunodeficiency virus--hiv (121) 121
virology (120) 120
female (119) 119
adult (115) 115
elvitegravir (108) 108
hiv-1 - drug effects (108) 108
hiv infections - virology (107) 107
antiretroviral drugs (104) 104
antiviral agents (104) 104
infection (100) 100
pharmacokinetics (100) 100
integrase (99) 99
drug therapy (98) 98
middle aged (97) 97
hiv infection (96) 96
heterocyclic compounds, 3-ring - therapeutic use (94) 94
aids/hiv (92) 92
drug resistance (89) 89
hiv-1 infection (87) 87
anti-hiv agents - therapeutic use (85) 85
hiv-1 (83) 83
initial treatment (83) 83
safety (83) 83
lamivudine (79) 79
drug resistance, viral (78) 78
integrase inhibitors (77) 77
hiv integrase inhibitors - pharmacology (74) 74
hiv integrase inhibitors - therapeutic use (74) 74
mutation (74) 74
integrase inhibitor (73) 73
efficacy (71) 71
therapy (70) 70
open-label (69) 69
hiv-1 - genetics (68) 68
naive adults (68) 68
heterocyclic compounds, 3-ring - administration & dosage (67) 67
efavirenz (63) 63
emtricitabine (62) 62
resistance (61) 61
non-inferiority trial (60) 60
anti-hiv agents - administration & dosage (59) 59
antiretroviral agents (59) 59
heterocyclic compounds, 3-ring - pharmacology (59) 59
heterocyclic compounds, 3-ring - adverse effects (58) 58
highly active antiretroviral therapy (57) 57
drug-resistance (56) 56
analysis (55) 55
adults (54) 54
treatment outcome (53) 53
tenofovir (52) 52
hiv integrase - genetics (51) 51
rilpivirine (51) 51
viral load (51) 51
co-formulated elvitegravir (50) 50
drug interactions (49) 49
patients (49) 49
tenofovir disoproxil fumarate (48) 48
abacavir (47) 47
acquired immune deficiency syndrome--aids (47) 47
health aspects (46) 46
protease inhibitors (46) 46
ritonavir (46) 46
clinical trials (43) 43
research (43) 43
dosage and administration (42) 42
human immunodeficiency virus (42) 42
non-inferiority (42) 42
care and treatment (41) 41
heterocyclic compounds, 3-ring - pharmacokinetics (41) 41
anti-hiv agents - adverse effects (40) 40
hiv integrase inhibitors - adverse effects (40) 40
cross-resistance (38) 38
hiv integrase - metabolism (38) 38
hiv integrase inhibitors - administration & dosage (38) 38
inhibitors (38) 38
young adult (38) 38
aids (37) 37
medicine, general & internal (37) 37
article (36) 36
hiv-1 - enzymology (36) 36
mutations (36) 36
drugs (35) 35
medical research (35) 35
aged (33) 33
genotype (33) 33
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (682) 682
Spanish (13) 13
French (6) 6
German (4) 4
Turkish (2) 2
Japanese (1) 1
Malay (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 2015, Volume 70, Issue 5, pp. 515 - 519
The SINGLE study was a randomized, double-blind, noninferiority study that evaluated the safety and efficacy of 50 mg dolutegravir + abacavir/lamivudine versus... 
Lamivudine | HIV | Abacavir | Dolutegravir | INFECTIOUS DISEASES | ONCE-DAILY DOLUTEGRAVIR | RALTEGRAVIR | ADULTS | abacavir | dolutegravir | IMMUNOLOGY | lamivudine
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 05/2018, Volume 66, Issue 11, pp. 1794 - 1797
In this randomized pilot clinical trial, dolutegravir plus lamivudine was noninferior to continuation of standard 3-drug maintenance antiretroviral therapy.... 
2-drug | maintenance therapy | Dolutegravir | lamivudine | Brief Reports
Journal Article
Clinica Chimica Acta, ISSN 0009-8981, 04/2018, Volume 479, pp. 56 - 65
Assessment of the unbound pharmacologically active fraction (fu; as the ratio of unbound to total concentration) of dolutegravir could improve therapeutic drug... 
Equilibrium dialysis | Unbound fraction | Dolutegravir | ELVITEGRAVIR | HEMOLYSIS | PROTEIN-BINDING | TANDEM MASS-SPECTROMETRY | HIV-SERONEGATIVE SUBJECTS | PHARMACOKINETICS | DRUGS | ANTIVIRAL ACTIVITY | SIMULTANEOUS QUANTIFICATION | MEDICAL LABORATORY TECHNOLOGY | INTEGRASE INHIBITOR DOLUTEGRAVIR | Index Medicus
Journal Article
Journal of Infectious Diseases, ISSN 0022-1899, 08/2014, Volume 210, Issue 3, pp. 354 - 362
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 08/2017, Volume 76, Issue 5, pp. 527 - 531
Journal Article
LANCET INFECTIOUS DISEASES, ISSN 1473-3099, 07/2014, Volume 14, Issue 7, pp. 572 - 580
Background Daily oral triple therapy is effective at halting HIV disease progression, but can have toxic effects and is costly. We investigated whether dual... 
INFECTIOUS DISEASES | RALTEGRAVIR | EFFICACY | SAFETY | ANALOGS | EFAVIRENZ | LOPINAVIR/RITONAVIR | DARUNAVIR/RITONAVIR | DOLUTEGRAVIR | SPARING REGIMEN | TENOFOVIR/EMTRICITABINE
Journal Article
HIV/AIDS - Research and Palliative Care, ISSN 1179-1373, 10/2019, Volume 11, pp. 255 - 263
Francis J Zamora,1,2 Ellen Dowers,2 Faiza Yasin,3 Onyema Ogbuagu3 1Department of Pharmacy Services, Broward Health Medical Center, Fort Lauderdale, FL, USA;... 
combination antiretroviral therapy | dolutegravir | lamivudine
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 05/2018, Volume 66, Issue 11, pp. 1689 - 1697
Limited data exist on initial human immunodeficiency virus type 1 (HIV-1) treatment with dolutegravir plus lamivudine. A5353 is a phase 2, single-arm, pilot... 
2-drug therapy | mutation | dolutegravir | naive | lamivudine | and Commentaries
Journal Article
Journal Article
Antiviral Research, ISSN 0166-3542, 12/2019, Volume 172, p. 104635
The accumulation of drug-resistance mutations on combined antiretroviral regimens (ART) backbone could affect the virological efficacy of the regimen. Our aim... 
Genotypic resistance test | M184V/I | Drug resistance | NNRTIs | Dolutegravir
Journal Article